[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-events\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-events":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,49,86,114,145,170,195,219,244,269],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100616300","phase-4-statins-to-prevent-cancer-associated-blood-clots-100616300",false,"NCT07303816","Statins to Prevent Cancer Associated Blood Clots","STAT-CAT: Statin Therapy to Prevent Cancer Associated Venous Thromboembolism","STAT-CAT","Inclusion Criteria:\n\n* age \\> 18 years with no contraindication to statin therapy and able to provide informed consent\n* newly diagnosed, newly recurrent or newly progressive malignancy with locally advanced\u002Fmetastatic disease initiating new systemic cancer therapy with no plan for prophylactic anticoagulation.\n* intermediate or high risk for cancer associated VTE based on the Khorana Score (KS) and modified Khorana Score (mKS) risk assessment tools (KS 2-4 or mKS 2-5).\n* ECOG performance status 0-2\n* Life expectancy \\> 6 months\n\nExclusion Criteria:\n\n* current use of statin therapy or known statin intolerance.\n* current use of systemic anticoagulation.\n* very low VTE risk defined by a Khorana Score (KS) of 0-1 and a modified Khorana Score (mKS) of 0-1.\n* extremely high VTE risk defined by a Khorana Score (KS) \\> 5 or modified Khorana Score (mKS) \\> 6 where guideline recommendations for systemic anticoagulation should be considered.\n* Basal cell or squamous cell carcinoma in situ cancers of the skin as the sole qualifying cancer type\n* ineligible cancer types where level of acuity is likely to preclude trial participation (including acute leukemia, myelodysplastic syndromes, primary brain tumors, primary CNS lymphoma, or plans to undergo hematopoietic stem cell transplantation or CAR-T cell therapy). (g) Known ALT, AST, or creatine kinase (CK) levels \\> 3 x ULN; eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m2, or Child Pugh Class B or C liver disease\n* Known hepatitis C or HIV disease, or intent to use certain oncologic agents (daralutemide, regorafenib, and cabozantinib) or some antivirals used to treat hepatitis C or HIV disease (combinations of sofosbuvir, velpatasvir, and voxilaprevir) which can significantly increase rosuvastatin exposure and potentially lead to drug-drug interactions (DDIs).\n* Conditions that, in the opinion of the investigator, would compromise the well-being of the subject or conduct of the study, including as examples life expectancy less than 6 months or an ECOG Performance Status \\> 3.","ALL","18 Years",{"count":20,"type":21},4000,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Patients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks. Thus, effective prophylaxis in oncology requires a method to reduce VTE without increasing hemorrhage.\n\nThe primary aim of the Statin Therapy to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT) trial is to test whether rosuvastatin 20 mg daily for 12 months compared to placebo can safely prevent VTE in patients with newly diagnosed or recently relapsed cancer who are at increased thrombotic risk, are not planned to be anticoagulated, and who do not otherwise take statin therapy.",[27,28,29],"Venous Thromboembolism","Cancer","Cardiovascular Events",[31,32,33,34,35,36],"statin","pulmonary embolism","rosuvastatin","cancer","venous thromboembolism","prophylactic anticoagulation","RECRUITING","2026-06-11",{"date":40,"type":41},"2026-06-12","ACTUAL",{"date":38,"type":41},{"date":44,"type":21},"2032-03-31",{"name":46,"class":47},"Brigham and Women's Hospital","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100589242","tezspire-cardiac-events-pass-100589242","NCT06951867","Tezspire Cardiac Events PASS","An Observational Multi-Country Post-Authorisation Safety Study to Evaluate the Risk of Serious Adverse Cardiovascular Events in Adolescent and Adult Patients With Severe Asthma Taking Tezepelumab","TRESPASS","Inclusion Criteria:\n\n* patients with a diagnosis of asthma receiving tezepelumab or high-intensity SOC treatment for severe asthma at any point during the study inclusion period.\n\nExclusion Criteria for both exposed and unexposed groups include:\n\n* \\\u003C12 months of data availability prior to index date,\n* age \\\u003C12 years at index date,\n* history of congenital heart disease or heart transplant outcome-specific exclusion criterion applied for each objective will include the presence of non-fatal myocardial infarction or stroke and the specific outcome of interest in the 180 days prior to index date\n* for comparative analysis, an additional exclusion criterion will be considered, i.e. exposure to non-tezepelumab biologics on index date or within the 5-half-life clearance period of the biologic\n* matching criteria (including, among other variables, the type and duration of SOC exposure in the 12 months before index date and propensity score \\[PS\\] matching) will be applied to ensure exposed and unexposed patients' comparability","12 Years","130 Years",{"count":60,"type":21},16640,"OBSERVATIONAL","The aim of this study is to evaluate the risk of serious adverse cardiovascular events in adolescent and adult patients with severe asthma taking tezepelumab compared to a population receiving standard of care treatment for severe asthma.",[29,64],"MACE",[66,67,68,69,70,71,72,73,74],"post Marketing Requirements (PMR) study","cardiovascular events","non-fatal myocardial infarction","non-fatal stroke","cardiovascular death","arrythmias","coronary artery disease","heart failure","myocardial disorders","2026-06-03",{"date":77,"type":41},"2026-06-04",{"date":79,"type":41},"2025-09-15",{"date":81,"type":21},"2029-05-31",{"name":83,"class":84},"AstraZeneca","INDUSTRY",4,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100597001","phase-3-aspirin-continuation-or-interruption-in-patients-at-moderate-risk-for-cardiovascular-events-undergoing-colonoscopy-andor-polypectomy-100597001","NCT07052799","Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and\u002For Polypectomy","Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and\u002For Polypectomy; a Placebo-controlled Trial","Inclusion Criteria:\n\n* patients receiving aspirin (80mg daily or more) for secondary prevention against cardiovascular diseases who require elective colonoscopy for colorectal cancer screening.\n\nExclusion Criteria:\n\n* patients who received a coronary stent of any type within 6 months\n* patients who had a cardiovascular event within 3 months\n* patients who had concurrent use of anticoagulants (warfarin or NOAC) or other antiplatelet drugs (P2Y12 receptor antagonists)\n* patient with bleeding diathesis e.g., hemophilia, von Willebrand's disease or coagulopathy from liver cirrhosis\n* patient with terminal malignancies or medical illnesses.\n* patient who is unable or refuse to give consents",{"count":94,"type":21},2514,[96],"PHASE3","One in 4 adults between 50 and 80 reports taking regular aspirin. The prevalence of aspirin uses increases with age as well as co-morbid vascular diseases. Patients with cardiovascular diseases are at risk of developing colorectal neoplasms. In patients undergoing screening colonoscopy, interruption of aspirin is believed to be associated with increased cardiovascular events. Continuation of aspirin can however be associated with an increased risk of post-polypectomy bleeding. International guidelines on periendoscopy management recommend the continuation of aspirin based on evidence from cohort studies, mostly retrospective, suggesting that the rate of bleeding is low. Cardiovascular complications from aspirin interruption can lead to disabilities and occasional deaths. The cardiovascular risks following aspirin continuation or interruption in endoscopy have not been well studied. There has been no randomized study to compare either strategy. Endoscopists are divided on their opinion on whether to stop or to continue aspirin. The proposed large randomized controlled trial (RCT) is powered to detect small differences in both outcomes. Findings from this RCT will address this important question and inform our clinical practice.",[99,29,100],"Myocardial Infarction (MI)","Post Polypectomy Bleeding in Antiplatelet Patients",[102,103,67],"Aspirin continuation or interruption","polypectomy","2026-03-16",{"date":106,"type":41},"2026-03-18",{"date":108,"type":41},"2026-02-10",{"date":110,"type":21},"2031-12-31",{"name":112,"class":47},"Chinese University of Hong Kong",1,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":125,"conditions":126,"keywords":130,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100582456","further-lipid-lowering-with-pcsk9-inhibitors-for-cardiovascular-outcomes-in-high-risk-coronary-plaques-assessed-by-ct-angiography-100582456","NCT06863545","Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography","FLAVOUR IV","Inclusion Criteria:\n\n1. Subject must be ≥ 18 years.\n2. Patients with at least one target lesion meet CCTA-detected plaque features of the following:\n\n   1. Degree of stenosis ≥ 50% or plaque burden ≥ 70%\n   2. At least 2 of the following high-risk plaque features:\n\n   i. Low-attenuation plaque ii. Positive remodeling iii. Napkin-ring sign iv. Spotty calcium\n3. The target lesion is located at the proximal or mid segment of left anterior descending artery, left circumflex artery or right coronary artery.\n4. Subject is able to confirm his\u002Fher understanding of the risks, benefits, and treatment alternatives of receiving study-related treatment. He\u002Fshe or his\u002Fher legally authorized representative provides written informed consent prior to any study-related procedure.\n\nExclusion Criteria:\n\n1. Target lesions underwent or planned to revascularization.\n2. Patients with acute coronary syndrome.\n3. New York Heart Association class III or IV, or last known left ventricular ejection fraction \\\u003C 30%.\n4. Uncontrolled or recurrent ventricular tachycardia.\n5. Homozygous familial hypercholesterolemia.\n6. Active liver disease or hepatic dysfunction.\n7. Failed CCTA plaque analysis.\n8. Non-cardiac co-morbid conditions with life expectancy \\\u003C 2 years.\n9. Pregnant and\u002For lactating women.\n10. Known hypersensitivity or contraindication to statin or PCSK9 inhibitors.",{"count":122,"type":21},3596,[124],"NA","The primary objective was to evaluate the effect of PCSK9 inhibitors in addition to the background lipid-modifying therapy (LMT), compared with standard LMT in terms of clinical outcomes in patients with coronary CT angiography (CCTA)-detected high-risk plaques.",[127,128,129,29],"Coronary Artery Disease","CT Angiography","PCSK9",[131,132,133,134],"PCSK9 inhibitors","Lipid-lowering therapy","High-Risk Coronary Plaques","Coronary CT angiography","2026-02-03",{"date":137,"type":41},"2026-02-06",{"date":139,"type":41},"2025-04-22",{"date":141,"type":21},"2033-04",{"name":143,"class":47},"Second Affiliated Hospital, School of Medicine, Zhejiang University",6,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":153,"targetDuration":155,"studyType":61,"phases":4,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100619813","cardiovascular-outcomes-and-risk-evaluation-among-recipients-of-hematopoietic-stem-cell-transplantation-100619813","NCT07349498","Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation","Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation (CORE-HCT): A Prospective Multicenter Observational Study","CORE-HCT","Inclusion Criteria:\n\n* Patients who undergo hematopoietic cell transplantation at any of the participating medical centers.\n\nExclusion Criteria:\n\n* Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data.\n* Patient request to withdraw from the study.",{"count":154,"type":21},10000,"5 Years","This is a prospective, multicenter observational study for recipients of hematopoietic stem cell transplantation. Patients who underwent hematopoietic stem cell transplantation at the participating centers will be entrolled in the study. The clinical characteristics, laboratory profiles, management measures, and clinical outcomes such as post-transplant cardiovascular events will be prospectively collected.",[158,159,29],"Hematopoietic Stem Cell Transplantation","Transplant Complication","2026-01-09",{"date":162,"type":41},"2026-01-16",{"date":164,"type":41},"2026-01-01",{"date":166,"type":21},"2036-12-31",{"name":168,"class":47},"Peking University People's Hospital",16,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":113},"100474413","pcsk-9-inhibitor-added-to-high-intensity-statin-therapy-to-prevent-cardiovascular-events-in-patients-with-acs-after-pci-100474413","NCT05457582","PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI","PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study","SHAWN","Inclusion Criteria:\n\n1. The subject, or their legal guardian, must have a clear understanding of the trial's design and treatment procedures. They must provide written informed consent before any trial-specific tests or procedures are conducted.\n2. Both male and female subjects aged ≥18 years.\n3. Subjects who have experienced an ACS and have undergone PCI for culprit lesions (either QFR or FFR \\\u003C 0.8) are eligible. ACS is defined as:\n\n(1) Unstable angina (characterized by rest pain lasting between 5 and 30 minutes or worsening exertional angina accompanied by either transient ST segment depression or elevation, or angiography revealing visually estimated diameter stenosis of 90% or greater, or a ruptured plaque or thrombotic lesion), or (2) Non-ST elevation myocardial infarction, indicated by positive troponin levels consistent with the clinical syndrome and non-ST segment elevation, or (3) ST elevation myocardial infarction, indicated by positive troponin levels consistent with the clinical syndrome and ST-segment elevation.\n\n4\\. Low-density lipoprotein cholesterol levels must meet the following criteria:\n\n1. Low-density lipoprotein cholesterol ≥70 mg\u002FdL (≥1.8 mmol\u002FL) in patients who have been on a stable high-intensity statin regimen for at least 4 weeks before enrollment.\n2. Low-density lipoprotein cholesterol ≥90 mg\u002FdL (≥2.3 mmol\u002FL) in patients who have been on a moderate or low-intensity statin regimen before enrollment.\n3. Low-density lipoprotein cholesterol ≥125 mg\u002FdL (≥3.2 mmol\u002FL) in patients who are statin-naïve or have not been on a stable statin regimen for at least 4 weeks before enrollment.\n\n5\\. Subjects must have at least one culprit lesion for ACS in a major native coronary artery (diameter stenosis \\>70% with a QFR or FFR\\\u003C0.8), and have at least one non-culprit vessel disease (diameter stenosis ≤70% with a QFR or FFR ≥0.8).\n\nExclusion Criteria:\n\n1. Fasting serum triglyceride levels exceeding 400 mg\u002FdL (exceeding 4.52 mmol\u002FL) before randomization.\n2. Coronary artery disease is located within a saphenous vein graft or an arterial graft.\n3. Residual diameter stenosis greater than 50% as determined by visual examination after percutaneous coronary intervention of the culprit lesion.\n4. TIMI (Thrombolysis in Myocardial Infarction) flow less than 3 in the culprit vessel after PCI.\n5. Unstable clinical status, characterized by hemodynamic (including cardiogenic shock) or electrical instability.\n6. Uncontrolled hypertension, indicated by multiple readings with systolic blood pressure (SBP) exceeding 180 mmHg or diastolic blood pressure (DBP) exceeding 110 mmHg.\n7. New York Heart Association (NYHA) Class III or IV, and an already known left ventricular ejection fraction (LVEF) below 30%.\n8. Known history of hemorrhagic stroke in last 180 days before randomization.\n9. Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response that has not been controlled by medications in the past 3 months before screening.\n10. Severe renal dysfunction, defined by an estimated glomerular filtration rate (eGFR) below 30 ml\u002Fmin\u002F1.73m².\n11. Active liver disease or hepatic dysfunction.\n12. Known intolerance to rosuvastatin or any statin.\n13. Known allergy to contrast medium, heparin, aspirin, ticagrelor, prasugrel, or clopidogrel.\n14. Subjects who have previously received PCSK9 inhibitors.\n15. Subjects who have received cholesterol ester transfer protein inhibitors within the past 12 months before enrollment.\n16. Treatment with systemic steroids or systemic cyclosporine within the past 3 months.\n17. Known active infection or major hematologic, metabolic, or endocrine dysfunction, as determined by the Investigator.\n18. Planned non-cardiac surgery within the next 12 months.\n19. Subjects who will not be able to attend the required study visits, as determined by the Investigator.\n20. Currently enrolled in another investigational device or drug study.\n21. History of cancer within the past 5 years, unless adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer.\n22. Estimated life expectancy of less than 12 months.\n23. Female of childbearing potential (age \\\u003C50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy, or hysterectomy.",{"count":179,"type":21},1212,[124],"The primary objective was to evaluate the effect of PCSK 9 Inhibitor (initiated within 4 h from PCI for the culprit lesion) with high-intensity statin treatment, compared to placebo with high-intensity statin treatment, on cardiovascular events (including cardiovascular death, myocardial infarction, stroke, re-hospitalization due to acute coronary syndromes or heart failure, or any ischemia-driven coronary revascularization) in patients with acute coronary syndrome and multiple lesions. Alirocumab was used before June 10, 2025; Tafolecimab has been used from June 10, 2025 onward.",[183,184,185,29],"Acute Coronary Syndrome","Hyperlipidemias","Percutaneous Coronary Intervention","2025-06-10",{"date":188,"type":41},"2025-06-13",{"date":190,"type":41},"2023-03-30",{"date":192,"type":21},"2030-09-30",{"name":194,"class":47},"Nanjing First Hospital, Nanjing Medical University",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":113},"100592855","phase-3-colchicine-in-chronic-kidney-disease-patients-100592855","NCT06998862","Colchicine in Chronic Kidney Disease Patients","Efficacy of Colchicine in Secondary Prevention of Vascular Events and Renal Progression in Patients With Moderate Chronic Kidney Disease","COLCHIREN","Inclusion Criteria:\n\nAge between 18 and 99 years. Moderate chronic kidney disease, defined as an estimated glomerular filtration rate (eGFR) by the CKD-EPI formula between 30 and 59 mL\u002Fmin\u002F1.73 m².\n\nHistory of a previous cardiovascular event:\n\nAcute coronary syndrome. Admission for angina pectoris. Transient ischemic attack or non-cardioembolic ischemic stroke. Coronary revascularization. Peripheral vasculopathy, defined as: embolism or acute peripheral arterial ischemia, or the need for amputation or surgical revascularization.\n\nFinding of coronary artery disease on imaging test.\n\nExclusion Criteria:\n\n* History of allergy or intolerance to colchicine or any of its excipients (dihydrate calcium hydrogen phosphate, microcrystalline cellulose, anhydrous colloidal silica, magnesium stearate).\n* Current treatment with colchicine, or within the month prior to inclusion.\n* Hospital admission for any cause within the 3 months prior to study inclusion.\n* Active malignant neoplasm (except non-melanoma skin cancer or carcinoma in situ). Patients with a history of malignant neoplasm who have remained disease-free for the past 3 years may be included.\n* Uncontrolled or symptomatic chronic inflammatory disease (rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, etc.).\n* Active infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus.\n* Liver cirrhosis of any cause, grade B or C according to Child-Pugh.\n* Immunosuppressive treatment within the 12 weeks prior to study inclusion.\n* Chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs).\n* Poorly controlled hypertension (\\>160\u002F90 mmHg) at the time of inclusion.\n* Pregnancy and breastfeeding at the time of inclusion. Contraceptive methods are required for women of reproductive age. Women with no capacity for pregnancy are considered to be those with:\n\nHistory of hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or bilateral tubal ligation.\n\nDocumented infertility. Postmenopausal women, defined as amenorrhea for more than 12 months without other medical cause. In case of doubt, confirmation with elevated follicle-stimulating hormone (FSH) levels is recommended.\n\nWomen of reproductive capacity must use a method of contraception with proven effectiveness until 8 weeks after the end of the study. Acceptable methods include:\n\nIntrauterine device (IUD) placement at least 6 weeks before study inclusion. Hormonal contraception with progestogens only, associated with ovulation inhibition: oral, injectable, or implantable, at least 6 weeks before study inclusion.\n\nProgestin-releasing intrauterine system (IUS) at least 6 weeks before study inclusion.\n\nCombined hormonal contraception (containing estrogen and progestogens) associated with ovulation inhibition: oral, intravaginal, transdermal, at least 6 weeks before study inclusion.\n\nOther contraceptive methods (sexual abstinence, barrier methods, spermicides, etc.) are not considered acceptable for participation in this study\n\n* Gastric ulcer\n* thrombocytopenia \\\u003C50,000 cells\u002FμL during the month prior to inclusion\n* Neutropenia defined as \\\u003C1500 cells\u002FmcL during the month prior to inclusion.\n* Anemia defined as hemoglobin \\\u003C10.5 g\u002FdL during the month prior to inclusion.\n* History of aplastic anemia diagnosed through bone marrow biopsy.\n* Treatment with CYP3A4 inhibitors and\u002For P-glycoprotein inhibitors (antivirals, azole antifungals, aminoglycosides, cyclosporine) in the month prior to their inclusion in the study.","99 Years",{"count":205,"type":21},744,[96],"The ColchiRen study is a phase 3, controlled, prospective, randomized, double-blind, and multicenter clinical trial. Its main objective is to demonstrate the benefit of low-dose colchicine treatment in secondary prevention of cardiovascular events in patients with moderate CKD. As a secondary objective, it aims to explore the potential beneficial anti-inflammatory effect on the progression of CKD.",[209,29],"Chronic Kidney Disease","2025-05-21",{"date":212,"type":41},"2025-05-31",{"date":214,"type":41},"2025-02-12",{"date":216,"type":21},"2028-12-30",{"name":218,"class":47},"Hospital General Universitario Gregorio Marañon",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":229,"conditions":230,"keywords":232,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":243},"100376584","tonometry1-and-duplex-ultrasound2-to-predict-cv-events-in-to-be-treated-patients-with-an-aaa-100376584","NCT04183426","Tonometry(1) and Duplex Ultrasound(2) to Predict CV Events in to be Treated Patients With an AAA","Tonometry(1) and Duplex Ultrasound(2) to Predict Cardiovascular Events in to be Treated Patients With an Abdominal Aortic Aneurysm (One-Two-Treat Trial)","One-Two-Treat","Inclusion Criteria:\n\n* Male or female at least 18 years old;\n* Informed consent form understood and signed and patient agrees to follow- up visits;\n* Has an infrarenal or juxtarenal abdominal aortic aneurysm (AAA), scheduled for elective repair (i.e open repair, EVAR, FEVAR and CHEVAR) according to standard practice;\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C 2 years;\n* Psychiatric or other condition that may interfere with the study;\n* Participating in another clinical study, interfering on outcomes;\n* Increased risk for coronary spasms (score Rose-questionnaire ≥2;\n* Presence of Raynaud's phenomenon, Marfan syndrome, chronic pain syndrome at upper extremity(s), presence of an AV fistula or shunt, open wounds to the upper extremity(s), and\u002For scleroderma associated with placing the hand in ice water;\n* Recent (\\\u003C3 months) presence of angina pectoris, myocardial infarction, cerebral infarction, and\u002For heart failure, or PAD treatment.",{"count":228,"type":21},194,"Abdominal aortic aneurysm (AAA) is a common vascular disease and associated with risk of rupture, but also with a high cardiovascular (CV) event rate. A key difficulty in AAA is predicting these life-threatening complications, which are strongly linked to vascular health. In 2013, the SMART risk score was developed to calculate the risk of the patients for recurrent vascular events based on clinical characteristics. Recently, a novel, easy to perform, non-invasive test of endothelial function (the carotid artery reactivity (CAR) test), reflecting target organ damage, has been introduced. The CAR is a simple, quick (5-min), non-invasive test that uses ultrasound to examine the carotid artery in response to sympathetic stimulation by placing one hand in cold water. This test shows strong agreement with both coronary and aortic responses to sympathetic stimulation and predicted CV-events in patients with peripheral arterial disease.\n\nThe aim of this prospective 2-year follow-up study is to investigate the predictive capacity of the CAR-test for development of CV-events after elective AAA repair in comparison to the SMART risk score. Secondary objectives are to investigate the predictive capacity of arterial stiffness measurements and the post-operative CAR-test for development of CV-events and to evaluate health status scores to provide insight if these scores can support clinical decision making.",[231,29],"Abdominal Aortic Aneurysm",[233,231,29],"Functional Response","2025-03-03",{"date":236,"type":41},"2025-03-06",{"date":238,"type":41},"2020-06-12",{"date":240,"type":21},"2027-06",{"name":242,"class":47},"Rijnstate Hospital",7,{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":17,"minAge":251,"maxAge":252,"enrollmentInfo":253,"targetDuration":255,"studyType":61,"phases":4,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":113},"100552452","evaluation-of-vulnerability-of-carotid-plaques-and-prediction-of-cardio-cerebrovascular-event-using-ultrasonic-imaging-100552452","NCT06473272","Evaluation of Vulnerability of Carotid Plaques and Prediction of Cardio-Cerebrovascular Event Using Ultrasonic Imaging","A Multi-center Prospective Cohort Study on the Evaluation of Vulnerability of Carotid Artery Plaques and Prediction of Cardio-Cerebrovascular Event Risk Using Ultrasonic Imaging","Inclusion Criteria:\n\n1. Patients who fully understand the purpose and significance of this experiment, voluntarily participate, and voluntarily sign the informed consent form;\n2. Patients over 40 years old;\n3. Patients with carotid plaque thickness ≥ 1.5 mm on conventional ultrasound, undergoing routine duplex ultrasound, contrast-enhanced ultrasound, ultrasound elastography, and three-dimensional ultrasound imaging.\n\nExclusion Criteria:\n\n1. Patients with severe cardiopulmonary insufficiency; allergy to sulfur hexafluoride; pregnant or lactating women; those with advanced tumors;\n2. Poor quality of ultrasound images;\n3. Patients who have previously undergone carotid artery stenting or endarterectomy on the same side as the carotid plaque.","40 Years","100 Years",{"count":254,"type":21},600,"36 Months","This study included patients with carotid artery atherosclerotic plaques to conduct multimodal ultrasound examinations, aiming to establish a plaque vulnerability assessment model based on ultrasonic imaging indicators, clinical history, and laboratory indicators. Based on the occurrence of cardiovascular and cerebrovascular events during the 3-year follow-up period, the correlation between the vulnerability of carotid plaques and the occurrence of cardiovascular and cerebrovascular events was explored. Furthermore, a cardiovascular and cerebrovascular risk prediction model for patients with plaques was established by combining multi-dimensional data indicators such as patients\\' clinical data and ultrasonic multimodal imaging data, forming a risk warning tool suitable for clinical use and providing a reference for risk management in patients with carotid artery plaques.\n\nResearch Objectives：\n\n1. To establish a plaque vulnerability assessment model based on ultrasonic imaging indicators of plaques, clinical indicators of patients, and laboratory indicators.\n2. To establish a cardiovascular and cerebrovascular risk prediction model for patients with carotid plaques by combining clinical indicators of patients and ultrasonic multimodal imaging data.\n3. To screen ultrasonic imaging indicators for predicting cardiovascular and cerebrovascular events.",[258,259,29],"Carotid Plaque","Ischemic Stroke","2024-12-03",{"date":262,"type":41},"2024-12-06",{"date":264,"type":41},"2024-07-01",{"date":266,"type":21},"2027-12-31",{"name":268,"class":47},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":275,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":278,"conditions":279,"keywords":283,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":113},"100514972","menopause-related-influences-on-leukocyte-distribution-monocyte-function-and-platelet-reactivity-100514972","NCT05985447","Menopause Related Influences on Leukocyte Distribution, Monocyte Function and Platelet Reactivity","Inclusion Criteria:\n\n* Age \\> 18 years\n* Male, female, diverse patients with current treatment in the Department of Cardiology, Pneumology and Angiology.\n* Persons who are able to understand and follow the instructions of the study staff\n* Written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Lack of written consent to participate in the study\n* coagulation disorders",true,{"count":277,"type":21},180,"Women and men show marked differences in cardiovascular risk profile and outcome. Women experience fewer cardiovascular events than men before menopause, but this relationship seems to reverse at menopause. These disparities are probably due to hormonal factors, especially the female sex hormone estrogen seems to have a protective influence on the development of atherosclerotic plaques premenopausal.\n\nThe underlying mechanisms of the effect of estrogens on the vessel wall are still insufficiently investigated. In this study, menopause related effects on leukocyte distribution and function as well on platelets and their aggregational response will be evaluated.",[280,281,29,282],"Arteriosclerosis","Acute Myocardial Infarction","Menopause",[284,285,286,287,288,289,290,67,291],"sex","gender","female","male","menopause","hormone replacement therapy","Atherosclerosis","cardiovascular risk","2023-08-02",{"date":294,"type":41},"2023-08-14",{"date":296,"type":41},"2022-03-07",{"date":298,"type":21},"2026-12",{"name":300,"class":47},"Heinrich-Heine University, Duesseldorf"]